Search

В работе изучалась возможность применения новой малоинвазивной методики регистрации ЭЭГ у крыс в литий-пилокарпиновой модели височной эпилепсии для выявления эпилептиформной активности в Ñ€Ð°Ð·Ð»Ð¸Ñ‡Ð½Ñ‹Ñ ÑÐºÑÐ¿ÐµÑ€Ð¸Ð¼ÐµÐ½Ñ‚Ð°Ð»ÑŒÐ½Ñ‹Ñ ÑƒÑÐ»Ð¾Ð²Ð¸ÑÑ . Было показано, что применение Ñ„ÑƒÐ½ÐºÑ†Ð¸Ð¾Ð½Ð°Ð»ÑŒÐ½Ñ‹Ñ Ð½Ð°Ð³Ñ€ÑƒÐ·Ð¾Ðº и депривации сна приводит к увеличению частоты Ð¾Ð´Ð¸Ð½Ð¾Ñ‡Ð½Ñ‹Ñ ÑÐ¿Ð°Ð¹ÐºÐ¾Ð² у ÑÐºÑÐ¿ÐµÑ€Ð¸Ð¼ÐµÐ½Ñ‚Ð°Ð»ÑŒÐ½Ñ‹Ñ ÐºÑ€Ñ‹Ñ в Ñ Ñ€Ð¾Ð½Ð¸Ñ‡ÐµÑÐºÑƒÑŽ фазу литий-пилокарпиновой модели височной эпилепсии.Â, In this work, has been studied the possibility of using a new original minimally invasive EEG recording technique in rats in a lithium-pilocarpine model of temporal lobe epilepsy to detect epileptiform activity under various experimental conditions. It was shown that the use of intermitter photic stimulation and auditory stimulation and sleep deprivation leads to an increase in the frequency of single spikes in experimental rats in the chromic phase of the lithium-pilocarpine model of temporal lobe epilepsy.Â

Over 50 million people worldwide have epilepsy. In nearly 30% of these cases, epilepsy remains unsatisfactorily controlled despite the availability of over 20 antiepileptic drugs. Moreover, no treatments exist to prevent the development of epilepsy in those at risk, despite an increasing understanding of the underlying molecular and cellular pathways. One of the major factors that have impeded rapid progress in these areas is the complex and multifactorial nature of epilepsy, and its heterogeneity. Therefore, the vision of developing targeted treatments for epilepsy relies upon the development of biomarkers that allow individually tailored treatment. Biomarkers for epilepsy typically fall into two broad categories: diagnostic biomarkers, which provide information on the clinical status of, and potentially the sensitivity to, specific treatments, and prognostic biomarkers, which allow prediction of future clinical features, such as the speed of progression, severity of epilepsy, development of comorbidities, or prediction of remission or cure. Prognostic biomarkers are of particular importance because they could be used to identify which patients will develop epilepsy and which might benefit from preventive treatments. Biomarker research faces several challenges; however, biomarkers could substantially improve the management of people with epilepsy and could lead to prevention in the right person at the right time, rather than just symptomatic treatment.